TUSTIN, Calif., Feb. 25 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company that, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical, health care and diagnostic products. The Company announced today that it has an updated, improved website at http://www.amdl.com/ .
Gary Dreher, CEO of AMDL, noted that "our new website significantly enhances and illuminates the compelling business that AMDL has built and is continuing to expand. We encourage anyone interested in gaining a better insight into our Company to visit http://www.amdl.com/. Later this year we anticipate that the websites for our Chinese subsidiaries and their products will also be updated in both English and Chinese." The new web site details all the Company's products, including cancer diagnostics, cancer therapy, anti-aging treatments, nutraceuticals and other therapies. It also provides information on the Company's management team, its business strategies and future objectives.
About Jade Pharmaceutical Inc.: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. Jade also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com/.
Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
VoiceMail: 714.505.4460
DATASOURCE: AMDL, Inc.
CONTACT: Mr. Paul Knopick, AMDL Investor Relations, +1-949-707-5365, VoiceMail, +1-714-505-4460
|